Opsynvi Patent Expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7094781 ACTELION Sulfamides and their use as endothelin receptor antagonists
Dec, 2025

(1 year, 4 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10946015 ACTELION Stable pharmaceutical compositions comprising a pyrimidine-sulfamide
Sep, 2026

(2 years from now)

US8268847 ACTELION Therapeutic compositions comprising a specific endothelin receptor antagonist and a PDE5 inhibitor
Apr, 2029

(4 years from now)



Opsynvi is a drug owned by Actelion Pharmaceuticals Us Inc. Opsynvi uses Macitentan; Tadalafil as an active ingredient. Opsynvi was launched by Actelion in 2024. It is is available in tablet form for oral use. Its generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Mar 22, 2031 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Mar 22, 2027
Orphan Drug Exclusivity(ODE-475) Mar 22, 2031

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using MACITENTAN; TADALAFIL ingredient

Market Authorisation Date: 22 March, 2024

Treatment: Use of the combination of macitentan and tadalafil for the chronic treatment of adults with pulmonary arterial hypertension; Method of treating pulmonary arterial hypertension comprising administering...

Dosage: TABLET

More Information on Dosage

OPSYNVI family patents

Family Patents